Cerus Corp (CERS) CMO sells 101,740 shares for RSU tax withholding

Rhea-AI Filing Summary

CERUS CORP Chief Medical Officer Benjamin Richard J reported an open-market sale of 101,740 shares of Common Stock at a weighted average price of $1.6572 per share. After this transaction, he directly holds 777,361 shares.

According to the footnotes, these shares were sold under an instruction intended to comply with Rule 10b5-1 that was elected on the grant date to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. The sales occurred in multiple trades at prices ranging from $1.62 to $1.73 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Benjamin Richard J

(Last) (First) (Middle)

C/O CERUS CORPORATION

1220 CONCORD AVE SUITE 600

(Street)

CONCORD CA 94520

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CERUS CORP [ CERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		S		101,740(1)	D	$1.6572(2)	777,361	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person.

2. Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.73 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.

	Richard J. Benjamin, by Chrystal N. Jensen, attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CERUS CORP (CERS) report for Benjamin Richard J?

CERUS CORP reported that Chief Medical Officer Benjamin Richard J sold 101,740 shares of Common Stock. The sale was executed as an open-market transaction linked to restricted stock unit vesting and related tax obligations, according to the explanatory footnotes.

At what price did the CERUS CORP CMO sell his CERS shares?

The CMO’s 101,740 shares were sold at a weighted average price of $1.6572 per share. Footnotes state the individual trades occurred between $1.62 and $1.73 per share, with details available upon request from the company or regulators.

How many CERUS CORP (CERS) shares does the CMO hold after this sale?

Following the sale, Chief Medical Officer Benjamin Richard J directly holds 777,361 CERUS CORP Common Stock shares. This figure reflects his remaining position after the 101,740 shares were sold in connection with restricted stock unit vesting.

Was the CERUS CORP insider sale under a Rule 10b5-1 trading plan?

Yes. Footnotes explain the shares were sold pursuant to an instruction intended to comply with Rule 10b5-1, elected on the grant date. The instruction covered statutory tax withholding obligations and brokerage fees from vesting restricted stock units.

Did the CERUS CORP CMO’s sale represent a discretionary decision to sell CERS stock?

Footnotes state the sale does not represent a discretionary sale by the reporting person. Instead, it was executed under a pre-established instruction to cover statutory tax withholding and brokerage fees linked to the vesting of restricted stock units.